CD123-targeted therapy in acute myeloid leukemia
Manuel Ricardo Espinoza-Gutarra1, Steven D Green1, Joshua F Zeidner2
1Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA.
Expert Review of Hematology
|May 27, 2021
Summary
Recent advancements in Acute myeloid leukemia (AML) treatment include new drug approvals and targeted therapies. CD123-targeted strategies show promise for improving outcomes in AML patients.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Acute myeloid leukemia (AML) is a cancer of hematopoietic stem cells.
- Therapeutic progress for AML has been limited until recent genomic discoveries.
- Conventional chemotherapy has been the primary AML treatment since the 1970s.
Purpose of the Study:
- To review recent clinical data on CD123-directed therapy in AML.
- To highlight the potential of novel agents in improving AML treatment efficacy and minimizing toxicity.
- To discuss the role of monoclonal antibodies targeting AML-specific surface markers.
Main Methods:
- Computerized PubMed search using relevant keywords.
- Review of abstracts from major hematology and oncology conferences (ASH, EHA, ASCO).
Main Results:
- CD123 (interleukin-3 receptor alpha chain) is highly expressed in AML, including the stem cell compartment.
- Several CD123-targeted therapies are currently under investigation in clinical trials.
- Monoclonal antibodies targeting CD123 are emerging as promising therapeutic candidates.
Conclusions:
- CD123 is a suitable therapeutic target for AML.
- Targeted therapies, particularly CD123-directed strategies, have the potential to improve AML patient outcomes.
- Ongoing clinical trials are evaluating novel agents to enhance AML treatment efficacy and reduce toxicity.
